多替拉韦用于艾滋病治疗的临床应用

肖然, 付强, 杜小莉, 李太生

中国药学杂志 ›› 2023, Vol. 58 ›› Issue (6) : 544-550.

PDF(1009 KB)
PDF(1009 KB)
中国药学杂志 ›› 2023, Vol. 58 ›› Issue (6) : 544-550. DOI: 10.11669/cpj.2023.06.012
论著

多替拉韦用于艾滋病治疗的临床应用

  • 肖然1a, 付强1a, 杜小莉1a*, 李太生1b,2*
作者信息 +

Clinical Application of Dolutegravir in the Treatment of AIDS

  • XIAO Ran1a, FU Qiang1a, DU Xiao-li1a*, LI Tai-sheng1b,2*
Author information +
文章历史 +

摘要

目的 通过分析多替拉韦(DTG)的临床试验数据,为优化基于DTG的抗反转录病毒疗法(ART)提供参考。方法 检索国内外有关DTG的文献,对DTG的药效学特性、药动学特性、安全性以及基于DTG的不同ART方案的疗效进行分析总结。结果 DTG具有强大的活性、良好的耐受性以及较高的耐药屏障。多项临床试验表明,基于DTG的二联法具有不劣于三联法的疗效和安全性。结论 DTG已成为目前ART中的核心药物,基于DTG的二联ART应用前景可观。

Abstract

OBJECTIVE To provide a reference for optimization of antiretroviral therapy (ART) based on dolutegravir (DTG) through analyzing clinical trial data of DTG. METHODS The literature at home and abroad about DTG was retrieved, and the pharmacodynamic properties, pharmacokinetic properties, safety, and efficacy of different DTG-based ART regimens were analyzed and summarized. RESULTS DTG has potent activity, good tolerability, and a high barrier to drug resistance. Multiple clinical trials have shown that DTG-based dual therapies have non-inferior efficacy and safety to triple therapies. CONCLUSION DTG has become the core drug in current ART, and the prospect of DTG-based dual ART is promising.

关键词

多替拉韦 / 整合酶抑制剂 / 抗反转录病毒疗法 / 获得性免疫缺陷综合征 / 艾滋病病毒

Key words

dolutegravir / integrase inhibitor / antiretroviral therapy / acquired immune deficiency syndrome / human immunodeficiency virus

引用本文

导出引用
肖然, 付强, 杜小莉, 李太生. 多替拉韦用于艾滋病治疗的临床应用[J]. 中国药学杂志, 2023, 58(6): 544-550 https://doi.org/10.11669/cpj.2023.06.012
XIAO Ran, FU Qiang, DU Xiao-li, LI Tai-sheng. Clinical Application of Dolutegravir in the Treatment of AIDS[J]. Chinese Pharmaceutical Journal, 2023, 58(6): 544-550 https://doi.org/10.11669/cpj.2023.06.012
中图分类号: R978.7   

参考文献

[1] HE N. Research progress in the epidemiology of HIV/AIDS in China. China CDC Wkly, 2021, 3(48):1022-1030.
[2] Acquired Immunodeficiency Syndrome and Hepatitis C Professional Group, Society of Infectious Diseases, Chinese Medical Association, Chinese Center for Disease Control and Prevention. Chinese guidelines for diagnosis and treatment of human immunodeficiency virus infection/acquired immunodeficiency syndrome (2021 edition). Chin J AIDS STD (中国艾滋病性病), 2021, 27(11):1182-1201.
[3] PHANUPHAK N, GULICK R M. HIV treatment and prevention 2019:current standards of care. Curr Opin HIV AIDS, 2020, 15(1):4-12.
[4] HARE S, SMITH S J, MÉTIFIOT M, et al. Structural and functional analyses of the second-generation integrase strand transfer inhibitor dolutegravir (S/GSK1349572). Mol Pharmacol, 2011, 80(4):565-572.
[5] MA S, GAO W L, ZHAO J, et al. Research progress in HIV-1 integrase inhibitors. Chin Pharm J(中国药学杂志), 2014, 49(21):1877-1881.
[6] WHO. Consolidated guidelines on HIV prevention, testing, treatment, service delivery and monitoring:recommendations for a public health approach. (2021-07-16):https://www.who.int/publications/i/item/9789240031593.
[7] KOBAYASHI M, YOSHINAGA T, SEKI T, et al. In vitro antiretroviral properties of S/GSK1349572, a next-generation HIV integrase inhibitor. Antimicrob Agents Chemother, 2011, 55(2):813-821.
[8] LLIBRE J M, PULIDO F, GARCÍA F, et al. Genetic barrier to resistance for dolutegravir. AIDS Rev, 2015, 17(1):56-64.
[9] MIN S, SONG I, BORLAND J, et al. Pharmacokinetics and safety of S/GSK1349572, a next-generation HIV integrase inhibitor, in healthy volunteers. Antimicrob Agents Chemother, 2010, 54(1):254-258.
[10] MIN S, SLOAN L, DEJESUS E, et al. Antiviral activity, safety, and pharmacokinetics/pharmacodynamics of dolutegravir as 10-day monotherapy in HIV-1-infected adults. AIDS, 2011, 25(14):1737-1745.
[11] LETENDRE S L, MILLS A M, TASHIMA K T, et al. ING116070:a study of the pharmacokinetics and antiviral activity of dolutegravir in cerebrospinal fluid in HIV-1-infected, antiretroviral therapy-naive subjects. Clin Infect Dis, 2014, 59(7):1032-1037.
[12] ADAMS J L, GREENER B N, KASHUBA A D. Pharmacology of HIV integrase inhibitors. Curr Opin HIV AIDS, 2012, 7(5):390-400.
[13] CASTELLINO S, MOSS L, WAGNER D, et al. Metabolism, excretion, and mass balance of the HIV-1 integrase inhibitor dolutegravir in humans. Antimicrob Agents Chemother, 2013, 57(8):3536-3546.
[14] ELLIOT E R, NEARY M, ELSE L, et al. Genetic influence of ABCG2, UGT1A1 and NR1I2 on dolutegravir plasma pharmacokinetics. J Antimicrob Chemother, 2020, 75(5):1259-1266.
[15] TSUCHIYA K, HAYASHIDA T, HAMADA A, et al. High plasma concentrations of dolutegravir in patients with ABCG2 genetic variants. Pharmacogenet Genomics, 2017, 27(11):416-419.
[16] VAN LUNZEN J, MAGGIOLO F, ARRIBAS J R, et al. Once daily dolutegravir (S/GSK1349572) in combination therapy in antiretroviral-naive adults with HIV:planned interim 48 week results from SPRING-1, a dose-ranging, randomised, phase 2b trial. Lancet Infect Dis, 2012, 12(2):111-118.
[17] ELLIOT E R, CERRONE M, CHALLENGER E, et al. Pharmacokinetics of dolutegravir with and without darunavir/cobicistat in healthy volunteers. J Antimicrob Chemother, 2019, 74(1):149-156.
[18] RAFFI F, RACHLIS A, STELLBRINK H J, et al. Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection:48 week results from the randomised, double-blind, non-inferiority SPRING-2 study. Lancet, 2013, 381(9868):735-743.
[19] CLOTET B, FEINBERG J, VAN LUNZEN J, et al. Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO):48 week results from the randomised open-label phase 3b study. Lancet, 2014, 383(9936):2222-2231.
[20] CALMY A, TOVAR SANCHEZ T, KOUANFACK C, et al. Dolutegravir-based and low-dose efavirenz-based regimen for the initial treatment of HIV-1 infection (NAMSAL):week 96 results from a two-group, multicentre, randomised, open label, phase 3 non-inferiority trial in Cameroon. Lancet HIV, 2020, 7(10):e677-e687.
[21] CAHN P, POZNIAK A L, MINGRONE H, et al. Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV:week 48 results from the randomised, double-blind, non-inferiority SAILING study. Lancet, 2013, 382(9893):700-708.
[22] ERON J J, CLOTET B, DURANT J, et al. Safety and efficacy of dolutegravir in treatment-experienced subjects with raltegravir-resistant HIV type 1 infection:24-week results of the VIKING Study. J Infect Dis, 2013, 207(5):740-748.
[23] ABOUD M, KAPLAN R, LOMBAARD J, et al. Dolutegravir versus ritonavir-boosted lopinavir both with dual nucleoside reverse transcriptase inhibitor therapy in adults with HIV-1 infection in whom first-line therapy has failed (DAWNING):an open-label, non-inferiority, phase 3b trial. Lancet Infect Dis, 2019, 19(3):253-264.
[24] VENTER W D F, SOKHELA S, SIMMONS B, et al. Dolutegravir with emtricitabine and tenofovir alafenamide or tenofovir disoproxil fumarate versus efavirenz, emtricitabine, and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection (ADVANCE):week 96 results from a randomised, phase 3, non-inferiority trial. Lancet HIV, 2020, 7(10):e666-e676.
[25] WALMSLEY S, BAUMGARTEN A, BERENGUER J, et al. Brief report:dolutegravir plus abacavir/lamivudine for the treatment of HIV-1 infection in antiretroviral therapy-naive patients:week 96 and week 144 results from the SINGLE randomized clinical Trial. J Acquir Immune Defic Syndr, 2015, 70(5):515-519.
[26] CAHN P, MADERO J S, ARRIBAS J R, et al. Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2):week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials. Lancet, 2019, 393(10167):143-155.
[27] TAIWO B O, MARCONI V C, BERZINS B, et al. Dolutegravir plus lamivudine maintains human immunodeficiency virus-1 suppression through week 48 in a pilot randomized trial. Clin Infect Dis, 2018, 66(11):1794-1797.
[28] VAN WYK J, AJANA F, BISSHOP F, et al. Efficacy and safety of switching to dolutegravir/lamivudine fixed-dose 2-drug regimen vs continuing a tenofovir alafenamide-based 3-or 4-drug regimen for maintenance of virologic suppression in adults living with human immunodeficiency virus type 1:phase 3, randomized, noninferiority TANGO study. Clin Infect Dis, 2020, 71(8):1920-1929.
[29] LING X M, CAI W P, ZHONG H L, et al. Real-world clinical efficacy and safety of simplified DTG+3TC dual regimen. Infect Dis Inf (传染病信息), 2022, 35(1):51-55.
[30] SCULIER D, WANDELER G, YERLY S, et al. Efficacy and safety of dolutegravir plus emtricitabine versus standard ART for the maintenance of HIV-1 suppression:48-week results of the factorial, randomized, non-inferiority SIMPL′HIV trial. PLoS Med, 2020, 17(11):e1003421.
[31] CAPETTI A F, COSSU M V, OROFINO G, et al. A dual regimen of ritonavir/darunavir plus dolutegravir for rescue or simplification of rescue therapy:48 weeks′ observational data. BMC Infect Dis, 2017, 17(1):658.
[32] SPINNER C D, KÜMMERLE T, SCHNEIDER J, et al. Efficacy and safety of switching to dolutegravir with boosted darunavir in virologically suppressed adults with HIV-1:a randomized, open-label, multicenter, phase 3, noninferiority trial:the DUALIS study. Open Forum Infect Dis, 2020, 7(9):ofaa356.
[33] ARMENIA D, BOUBA Y, GAGLIARDINI R, et al. Virological response and resistance profile in highly treatment-experienced HIV-1-infected patients switching to dolutegravir plus boosted darunavir in clinical practice. HIV Med, 2021, 22(6):519-525.
[34] LLIBRE J M, HUNG C C, BRINSON C, et al. Efficacy, safety, and tolerability of dolutegravir-rilpivirine for the maintenance of virological suppression in adults with HIV-1:phase 3, randomised, non-inferiority SWORD-1 and SWORD-2 studies. Lancet, 2018, 391(10123):839-849.
[35] ABOUD M, ORKIN C, PODZAMCZER D, et al. Efficacy and safety of dolutegravir-rilpivirine for maintenance of virological suppression in adults with HIV-1:100-week data from the randomised, open-label, phase 3 SWORD-1 and SWORD-2 studies. Lancet HIV, 2019, 6(9):e576-e587.
[36] VAN WYK J, ORKIN C, RUBIO R, et al. Brief report:durable suppression and low rate of virologic failure 3 years after switch to dolutegravir+rilpivirine 2-drug regimen:148-week results from the SWORD-1 and SWORD-2 randomized clinical trials. J Acquir Immune Defic Syndr, 2020, 85(3):325-330.
[37] NASREDDINE R, YOMBI J C, DARCIS G, et al. Efficacy, durability, and tolerability of dolutegravir/lamivudine and dolutegravir/rilpivirine for the treatment of HIV in a real-world setting in Belgium. HIV Med, 2022,1-12. Doi: 10.1111/hiv.13373.
[38] CHEN ZH, LI Y, TAN S, et al. A case of Albuvirtide combined with dolutegravir in a patient with AIDS intolerant to multiple antiretroviral drugs. Chin J AIDS STD (中国艾滋病性病), 2022, 28(7):846-847.
[39] WIJTING I, ROKX C, BOUCHER C, et al. Dolutegravir as maintenance monotherapy for HIV (DOMONO):a phase 2, randomised non-inferiority trial. Lancet HIV, 2017, 4(12):e547-e554.
[40] COTTRELL M L, HADZIC T, KASHUBA A D. Clinical pharmacokinetic, pharmacodynamic and drug-interaction profile of the integrase inhibitor dolutegravir. Clin Pharmacokinet, 2013, 52(11):981-994.
[41] ELZI L, ERB S, FURRER H, et al. Adverse events of raltegravir and dolutegravir. AIDS, 2017, 31(13):1853-1858.
[42] HILL A M, MITCHELL N, HUGHES S, et al. Risks of cardiovascular or central nervous system adverse events and immune reconstitution inflammatory syndrome, for dolutegravir versus other antiretrovirals:meta-analysis of randomized trials. Curr Opin HIV AIDS, 2018, 13(2):102-111.
[43] KHELOUFI F, BOUCHERIE Q, BLIN O, et al. Neuropsychiatric events and dolutegravir in HIV patients:a worldwide issue involving a class effect. AIDS, 2017, 31(12):1775-1777.
[44] BOURGI K, REBEIRO P F, TURNER M, et al. Greater weight gain in treatment-naive persons starting dolutegravir-based antiretroviral therapy. Clin Infect Dis, 2020, 70(7):1267-1274.
[45] MILIC J, RENZETTI S, FERRARI D, et al. Relationship between weight gain and insulin resistance in people living with HIV switching to integrase strand transfer inhibitors-based regimens. AIDS, 2022, 36(12):1643-1653.
[46] NHEAN S, YOONG D, WONG D K, et al. Probable hepatotoxicity with dolutegravir:report of two cases and review of the literature. AIDS, 2019, 33(7):1261-1263.
[47] WELLER S, BORLAND J, CHEN S, et al. Pharmacokinetics of dolutegravir in HIV-seronegative subjects with severe renal impairment. Eur J Clin Pharmacol, 2014, 70(1):29-35.
[48] SONG I H, BORLAND J, SAVINA P M, et al. Pharmacokinetics of single-dose dolutegravir in HIV-seronegative subjects with moderate hepatic impairment compared to healthy matched controls. Clin Pharmacol Drug Dev, 2013, 2(4):342-348.
[49] CAHN P. Candidates for inclusion in a universal antiretroviral regimen:dolutegravir. Curr Opin HIV AIDS, 2017, 12(4):318-323.
[50] TURKOVA A, WHITE E, MUJURU H A, et al. Dolutegravir as first-or second-line treatment for HIV-1 infection in children. N Engl J Med, 2021, 385(27):2531-2543.
[51] RUEL T D, ACOSTA E P, LIU J P, et al. Pharmacokinetics, safety, tolerability, and antiviral activity of dolutegravir dispersible tablets in infants and children with HIV-1 (IMPAACT P1093):results of an open-label, phase 1-2 trial. Lancet HIV, 2022, 9(5):e332-e340.
[52] WAITT C, ORRELL C, WALIMBWA S, et al. Safety and pharmacokinetics of dolutegravir in pregnant mothers with HIV infection and their neonates:a randomised trial (DolPHIN-1 study). PLoS Med, 2019, 16(9):e1002895.
[53] MALABA T R, NAKATUDDE I, KINTU K, et al. 72 weeks post-partum follow-up of dolutegravir versus efavirenz initiated in late pregnancy (DolPHIN-2):an open-label, randomised controlled study. Lancet HIV, 2022, 9(8):e534-e543.
[54] Panel on Treatment of HIV During Pregnancy and Prevention of Perinatal Transmission. Recommendations for the use of antiretroviral drugs during pregnancy and interventions to reduce perinatal HIV transmission in the United States. (2021-12-30):https://clinicalinfo.hiv.gov/es/node/9210.
[55] ZASH R, MAKHEMA J, SHAPIRO R L. Neural-tube defects with dolutegravir treatment from the time of conception. N Engl J Med, 2018, 379(10):979-981.

基金

十三五国家科技重大专项课题-艾滋病综合治疗方案的优化及推广应用研究项目资助(2017ZX10202101)
PDF(1009 KB)

Accesses

Citation

Detail

段落导航
相关文章

/